Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference

Kidney International

Volumn 92, Issue 2, 2017, Pages 297-305

  Baigent, Colin ^a   Herrington, William G ^a   Coresh, Josef ^b   Landray, Martin J ^a   Levin, Adeera ^c   Perkovic, Vlado ^d   Pfeffer, Marc A ^e   Rossing, Peter ^f,g   Walsh, Michael ^h   Wanner, Christoph ⁱ   Wheeler, David C ^j   Winkelmayer, Wolfgang C ^k   McMurray, John J V ^l   Abu Alfa, Ali ^m   Archdeacon, Patrick ^m   Block, Geoffrey A ^m   Caskey, Fergus J ^m   Cheung, Alfred K ^m   Cooper, Bruce ^m   Craig, Jonathan C ^m   Dember, Laura M ^m   Eknoyan, Garabed ^m   Gansevoort, Ron T ^m   Gill, John S ^m   Gillespie, Barbara ^m   Greene, Tom ^m   Harris, David C ^m   Haynes, Richard ^m   Hemmelgarn, Brenda R ^m   Herzog, Charles A ^m   Hiemstra, Thomas F ^m   Inker, Lesley A ^m   Jardine, Meg J ^m   Jha, Vivekanand ^m   Jiang, Lixin ^m   Johansen, Kirsten L ^m   Kewalramani, Reshma ^m   Lambers Heerspink, Hiddo J ^m   Lefkowitz, Martin ^m   Lok, Charmaine E ^m   Loud, Fiona ^m   Mačiulaitis, Romaldas ^m   Maddux, Dugan W ^m   Maddux, Franklin W ^m   Madero, Magdalena ^m   Mariz, Segundo ^m   Mauer, Michael ^m   Nally, Joseph V ^m   Nangaku, Masaomi ^m   Okpechi, Ikechi G ^m   Parfrey, Patrick S ^m   Pecoits Filho, Roberto ^m   Pereira, Brian J G ^m   Rocco, Michael V ^m   Rossignol, Patrick ^m   Schaefer, Franz ^m   Tentori, Francesca ^m   Thompson, Aliza ^m   Tonelli, Marcello ^m   Tong, Allison ^m   Toto, Robert D ^m   Tuttle, Katherine R ^m   Vetter, Thorsten ^m   Moon Wang, Angela Yee ^m   Zannad, Faiez ^m   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF SYDNEY   (Australia)

^e HARVARD MEDICAL SCHOOL   (United States)

^f STENO DIABETES CENTER   (Denmark)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h HAMILTON HEALTH SCIENCES   (Canada)

ⁱ UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l UNIVERSITY OF GLASGOW   (United Kingdom)

^m NONE

more..

Author keywords

kidney disease; randomized clinical trials; trial conduct; trial design

Indexed keywords

COMORBIDITY; CONFERENCE PAPER; DISEASE COURSE; FOLLOW UP; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PATIENT RIGHT; PATIENT SAFETY; PRIORITY JOURNAL; PROFESSIONAL STANDARD; SAMPLE SIZE; WELLBEING; CLINICAL TRIAL (TOPIC); NEPHROLOGY;

CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY DISEASES; NEPHROLOGY;

EID: 85024388262     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2017.04.019     Document Type: Conference Paper

References (39)

1. Eckardt, K.U., Coresh, J., Devuyst, O., et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382 (2013), 158–169.
2. National Kidney Foundation. Global Facts: About Kidney Disease. Available at: https://www.kidney.org/kidneydisease/global-facts-about-kidney-disease. Accessed February 6, 2017.
3. Collins, A.J., Foley, R.N., Herzog, C., et al. US Renal Data System 2012 Annual Data Report. Am J Kidney Dis, 61(suppl 1), 2013, A7 e1–e476.
4. Kerr, M., Bray, B., Medcalf, J., et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant 27:suppl 3 (2012), iii73–iii80.
5. Global Burden of Diseases 2013 Mortality and Causes of Death Collaboration. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
6. Alegre-Diaz, J., Herrington, W., Lopez-Cervantes, M., et al. Diabetes and cause-specific mortality in Mexico City. N Engl J Med 375 (2016), 1961–1971.
7. Bellomo, R., Kellum, J.A., Ronco, C., Acute kidney injury. Lancet 380 (2012), 756–766.
8. Kellum, J.A., Ronco, C., Bellomo, R., Acute kidney disease and the community. Lancet 387 (2016), 1974–1976.
9. Romero, V., Akpinar, H., Assimos, D.G., Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 12 (2010), e86–e96.
10. Inrig, J.K., Califf, R.M., Tasneem, A., et al. The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am J Kidney Dis 63 (2014), 771–780.
11. Nabel, E.G., Braunwald, E., A tale of coronary artery disease and myocardial infarction. N Engl J Med 366 (2012), 54–63.
12. Collins, R., MacMahon, S., Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet 357 (2001), 373–380.
13. Haynes, R., Landray, M.J., Herrington, W.G., Baigent, C., Clinical trials: why and how in nephrology. Turner, N., Lamiere, N., Goldsmith, D.J., Winearls, C.G., Hemmelfarb, J., Remuzzi, G., (eds.) Oxford Textbook of Clinical Nephrology, 2015, Oxford University Press, New York, NY vol. 1:161–167.
14. Baigent, C., Landray, M.J., Reith, C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377 (2011), 2181–2192.
15. Chertow, G.M., Block, G.A., Correa-Rotter, R., et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 (2012), 2482–2494.
16. Parfrey, P.S., Block, G.A., Correa-Rotter, R., et al. Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. Clin J Am Soc Nephrol 11 (2016), 539–546.
17. Lang, J.M., Buring, J.E., Rosner, B., et al. Estimating the effect of the run-in on the power of the Physicians' Health Study. Stat Med 10 (1991), 1585–1593.
18. Egger, M., Smith, G.D., Misleading meta-analysis. BMJ 311 (1995), 753–754.
19. Moxey-Mims, M.M., Flessner, M.F., Holzman, L., et al. Glomerular diseases: registries and clinical trials. Clin J Am Soc Nephrol 11 (2016), 2234–2243.
20. Pocock, S.J., Stone, G.W., The primary outcome fails - what next?. N Engl J Med 375 (2016), 861–870.
21. Coresh, J., Turin, T.C., Matsushita, K., et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311 (2014), 2518–2531.
22. Torres, V.E., Chapman, A.B., Devuyst, O., et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367 (2012), 2407–2418.
23. U.S. Food and Drug Administration. Guidance for Industry: Qualification of Biomarker: Total Kidney Volume in Studies for Treatment of Autosomal Dominant Polycystic Kidney Disease, 2016. Available at: https://www.fda.gov/downloads/Drugs/Guidances/UCM458483.pdf. Accessed June 16, 2017.
24. Levey, A.S., Inker, L.A., Matsushita, K., et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 64 (2014), 821–835.
25. European Medicine Agency. Reflection paper on extrapolation of efficacy and safety in paediatric medicine development. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/04/WC500204187.pdf. Accessed January 25, 2017.
26. Thompson, A., Proteinuria as a surrogate end point–more data are needed. Nat Rev Nephrol 8 (2012), 306–309.
27. Heerspink, H.J., Kropelin, T.F., Hoekman, J., et al. Reducing albuminuria as surrogate endpoint C. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 26 (2015), 2055–2064.
28. NKF-FDA-EMA Workshop. Available at: https://www.kidney.org/CKDEndpoints. Accessed March 5, 2017.
29. Standardised Outcomes in Nephrology (SONG). Available at: http://songinitiative.org/. Accessed January 25, 2017.
30. Standardised Outcomes in Nephrology-HD Consensus Workshop. Available at: http://songinitiative.org/about-us/song-hd/. Accessed September 10, 2016.
31. U.S. Food and Drugs Administration. Guidance for Industry: Patient-Reported Outcomes Measures: Use in Medical Product Development to Support Labeling Claims. Available at: www.fda.gov/downloads/drugs/guidances/ucm193282.pdf. Accessed January 25, 2017.
32. Rogers, J.K., Yaroshinsky, A., Pocock, S.J., et al. Analysis of recurrent events with an associated informative dropout time: application of the joint frailty model. Stat Med 35 (2016), 2195–2205.
33. Frobert, O., Lagerqvist, B., Olivecrona, G.K., et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 369 (2013), 1587–1597.
34. Clinical Trial Transformation Initiative (CTTI). QBD (Quality by Design) Toolkit. Available at: https://www.ctti-clinicaltrials.org/toolkit/qbd. Accessed January 25, 2017.
35. Meeker-O'Connell, A., Glessner, C., Behm, M., et al. Enhancing clinical evidence by proactively building quality into clinical trials. Clin Trials 13 (2016), 439–444.
36. Ndounga Diakou, L.A., Trinquart, L., Hrobjartsson, A., et al. Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates. Cochrane Database Syst Rev, 3, 2016 Mar 10, MR000043.
37. Hlatky, M.A., Ray, R.M., Burwen, D.R., et al. Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. Circ Cardiovasc Qual Outcomes 7 (2014), 157–162.
38. Pogue, J.M., Devereaux, P.J., Thorlund, K., Yusuf, S., Central statistical monitoring: detecting fraud in clinical trials. Clin Trials 10 (2013), 225–235.
39. Landray, M.J., Bax, J.J., Alliot, L., et al. Improving public health by improving clinical trial guidelines and their application. Eur Heart J 38 (2017), 1632–1637.